CONTRATOS RIO HORTEGA
Datos básicos
- Protocolo:
- CM15/00246
- EUDRACT:
- NCT:
- Centro:
- Año de incio:
- Año de finalización:
- 2018
Documentos
- No hay documentos
Participantes
Grupos y Plataformas de I+D+i
Financiadores - Promotores
INSTITUTO SALUD CARLOS III
Resultados del Ensayo Clínico
Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes
Ragulan, C; (...); Sadanandam, A
Article. 10.1038/s41598-019-43492-0. 2019
Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences.
Henriksen, Tenna Vesterman; (...); Andersen, Claus Lindbjerg
Article. 10.1158/1078-0432.CCR-21-2404. 2022
Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer.
Tarazona, Noelia; (...); Cervantes, Andres
Article. 10.1136/esmoopen-2020-000847. 2020
Improving tumor budding evaluation in colon cancer by extending the assessment area in colectomy specimen.
Martinez-Ciarpaglini, Carolina; (...); Cervantes, Andres
Article. 10.1111/his.13900. 2019
Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression
Martinez-Ciarpaglini, C; (...); Cervantes, A
Article. 10.1038/s41379-018-0124-5. 2019
NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2 -Amplified Gastric Cancer.
Gambardella, V; (...); Cervantes, A
Article. 10.1158/1078-0432.CCR-18-2421. 2019
Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress.
Gambardella, Valentina; (...); Cervantes, Andres
Article. 10.3390/jcm9093049. 2020
Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer
Tarazona, N; (...); Cervantes, A
Article. 10.1093/annonc/mdz390. 2019
Towards precision oncology for anti-HER2 blockade in gastroesophageal adenocarcinoma.
Gambardella, V; (...); Cervantes, A
Review. 10.1093/annonc/mdz143. 2019